Fatty acid-binding protein 5
Homo sapiens
当前结构中的状态
| Assembly | 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与共同组分 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|
| 1 | 蛋白单体 单体 蛋白 × 1 PDB 声明:monomeric(1) 与蛋白拷贝数一致 | 链 A; UniProt 1–135 | 未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 2 IOV (1R,2S)-2-{[5-carbamoyl-3-(ethoxycarbonyl)-4-methylthiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid × 1 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368 | 分辨率 1.24 Å R-free 0.201 |
数据库中的同蛋白其他状态
以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly, “相对当前条目”直接指出证据层面的不同;没有差异标签表示当前已读取字段一致。
| 其他 PDB | 相对当前条目 7G1Q | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 1B56 HUMAN RECOMBINANT EPIDERMAL FATTY ACID BINDING PROTEIN 提交 1999-01-12 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | PLM PALMITIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
pH 6;pH 6.0
|
分辨率 2.05 Å R-free 0.260 |
| 1JJJ SOLUTION STRUCTURE OF RECOMBINANT HUMAN EPIDERMAL-TYPE FATTY ACID BINDING PROTEIN 提交 2001-07-06 | 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | 未记录非水小分子 |
SOLUTION NMR
NMR测量条件
pH 5.6;298 K;离子强度(mmCIF原始值)20 mM POTASSIUM PHOSPHATE;压力 AMBIENT
NMR样品组成
1.5-2 MM E-FABP PHOSPHATE BUFFER; 0.05% SODIUM AZIDE
|
分辨率未提供 |
| 4AZM Human epidermal fatty acid-binding protein (FABP5) in complex with the inhibitor BMS-309413 提交 2012-06-26 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 A
1–135(135 aa)
链 B
1–135(135 aa)
|
未记录 | T4B ((2'-(5-ETHYL-3,4-DIPHENYL-1H-PYRAZOL-1-YL)-3-BIPHENYLYL)OXY)ACETIC ACID × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.32 M SODIUM CITRATE, 0.1 M HEPES PH 7.0, SATURATED WITH RESPECT TO BMS-309403, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K. CRYOPROTECTION: 28% GLYCEROL IN MOTHER LIQUOR.
|
分辨率 2.75 Å R-free 0.252 |
| 4AZR Human epidermal fatty acid-binding protein (FABP5) in complex with the endocannabinoid anandamide 提交 2012-06-26 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 A
1–135(135 aa)
链 B
1–135(135 aa)
|
未记录 | A9M N-(2-hydroxyethyl)icosanamide × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
pH 7.5;25% PEG 3350, 0.1 M HEPES PH 7.5. FABP INCUBATED IN A SOLUTION SATURATED WITH RESPECT TO ANANDAMIDE PRIOR TO CRYSTALLIZATION. CRYPROTECTION: 25% GLYCEROL IN MOTHER LIQUOR.
|
分辨率 2.95 Å R-free 0.268 |
| 4LKP Crystal Structure of Apo Human Epidermal Fatty Acid Binding Protein (FABP5) 提交 2013-07-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | CL CHLORIDE ION × 1 DMS DIMETHYL SULFOXIDE × 2 NH4 AMMONIUM ION × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;291 K;2.0M ammonium sulfate, 300mM Na/K tartrate, 100mM Na citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
分辨率 1.67 Å R-free 0.214 |
| 4LKT Crystal Structure of Human Epidermal Fatty Acid Binding Protein (FABP5) in Complex with Linoleic Acid 提交 2013-07-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | EIC LINOLEIC ACID × 1 GOL GLYCEROL × 4 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;2.4M Ammonium Sulfate, 200mM Na/K Tartrate, 100mM Na Citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
分辨率 2.57 Å R-free 0.259 |
| 4LKT Crystal Structure of Human Epidermal Fatty Acid Binding Protein (FABP5) in Complex with Linoleic Acid 提交 2013-07-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–135(135 aa)
|
未记录 | EIC LINOLEIC ACID × 1 GOL GLYCEROL × 1 CL CHLORIDE ION × 1 TAR D(-)-TARTARIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;2.4M Ammonium Sulfate, 200mM Na/K Tartrate, 100mM Na Citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
分辨率 2.57 Å R-free 0.259 |
| 4LKT Crystal Structure of Human Epidermal Fatty Acid Binding Protein (FABP5) in Complex with Linoleic Acid 提交 2013-07-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–135(135 aa)
|
未记录 | EIC LINOLEIC ACID × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 1 TAR D(-)-TARTARIC ACID × 1 CIT CITRIC ACID × 1 NH4 AMMONIUM ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;2.4M Ammonium Sulfate, 200mM Na/K Tartrate, 100mM Na Citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
分辨率 2.57 Å R-free 0.259 |
| 4LKT Crystal Structure of Human Epidermal Fatty Acid Binding Protein (FABP5) in Complex with Linoleic Acid 提交 2013-07-08 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 D
1–135(135 aa)
|
未记录 | EIC LINOLEIC ACID × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 1 TAR D(-)-TARTARIC ACID × 1 NH4 AMMONIUM ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;277 K;2.4M Ammonium Sulfate, 200mM Na/K Tartrate, 100mM Na Citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
分辨率 2.57 Å R-free 0.259 |
| 5HZ5 FABP5 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline 提交 2016-02-02 | 构建体不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
2–135(134 aa)
片段:SOLUBLE FORM, RESIDUES 2-135
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 1 65X 6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;295 K
|
分辨率 1.40 Å R-free 0.228 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 3 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 2 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 2 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 D
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 2 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 5 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 E
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 6 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 F
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 7 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 G
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 2 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 5UR9 Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5 提交 2017-02-09 | 配体/离子不同 实验环境不同 结构质量不同 | Assembly 8 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 H
1–135(135 aa)
|
未记录 | 8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1 SO4 SULFATE ION × 1 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å R-free 0.237 |
| 7FWI Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å R-free 0.273 |
| 7FWI Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–135(135 aa)
|
未记录 | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å R-free 0.273 |
| 7FWI Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 C
1–135(135 aa)
|
未记录 | NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å R-free 0.273 |
| 7FXD Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.44 Å R-free 0.280 |
| 7FY0 Crystal Structure of human FABP5 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid, i.e. SMILES c1(cc(cc(c1c1ccccc1)Cl)Cl)NC(=O)N1CCC[C@@H]1C(=O)O with IC50=18 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 3 UOF 1-[(4,6-dichloro[1,1'-biphenyl]-2-yl)carbamoyl]-D-proline × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.34 Å R-free 0.192 |
| 7FYD Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-propan-2-ylquinoline-3-carboxylic acid, i.e. SMILES c1(ccc2c(c1)c(c1ccccc1)c(c(n2)C(C)C)C(=O)O)Cl with IC50=2.6 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 2 VLQ 6-chloro-4-phenyl-2-(propan-2-yl)quinoline-3-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.45 Å R-free 0.223 |
| 7G01 Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-piperidin-1-ylquinoline-3-carboxylic acid, i.e. SMILES n1c(c(c(c2c1ccc(c2)Cl)c1ccccc1)C(=O)O)N1CCCCC1 with IC50=1.1 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 1 5M7 6-chloranyl-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid × 2 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.17 Å R-free 0.171 |
| 7G04 Crystal Structure of human FABP5 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid, i.e. SMILES c12c(ccc(c2)c2ccc(cc2)Cl)CCC[C@H]1C(=O)O with IC50=3.3 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.40 Å R-free 0.220 |
| 7G04 Crystal Structure of human FABP5 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid, i.e. SMILES c12c(ccc(c2)c2ccc(cc2)Cl)CCC[C@H]1C(=O)O with IC50=3.3 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 B
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 1 CL CHLORIDE ION × 1 WXZ (1R)-7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.40 Å R-free 0.220 |
| 7G0B Crystal Structure of human FABP5 in complex with 7-bromo-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1-benzazepine-4-carboxylic acid, i.e. SMILES [C@@H]1([C@@H](CCN(c2c1cc(cc2)Br)C)C(=O)O)c1ccccc1 with IC50=2.3 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 SO4 SULFATE ION × 1 WK0 (4S,5S)-7-bromo-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.47 Å R-free 0.219 |
| 7G0E Crystal Structure of human FABP5 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid, i.e. SMILES C1CCC2=C(C1)C(=C(S2)NC(=O)C1=C(C(=O)O)CCC1)C(=O)OCC with IC50=1.1 microM 提交 2023-04-27 | 配体/离子不同 结构质量不同 | Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric |
链 A
1–135(135 aa)
|
未记录 | DMS DIMETHYL SULFOXIDE × 1 L8T 2-{[3-(ethoxycarbonyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid × 2 SO4 SULFATE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.11 Å R-free 0.191 |
共 16 个其他 PDB 条目、29 个 assembly。 打开独立比较页并筛选聚集状态
查看构建体与数据证据
| UniProt名称 | FABP5_HUMAN |
| Isoform | — |
| PDB实体 | 1 |
| 链与序列区间 | 作者链 A; PDB构建体 4–138; UniProt 1–135 |